Fenfluramine-induced immunosuppression: an in vivo analysis

被引:6
作者
Connor, TJ [1 ]
Kelly, JP [1 ]
机构
[1] Natl Univ Ireland Univ Coll Galway, Dept Pharmacol, Galway, Ireland
关键词
fenfluramine; lipopolysaccharide; interleukin-1; beta; TNF-alpha (tumor necrosis factor-alpha); interleukin-10; glucocorticoid; catecholamine;
D O I
10.1016/S0014-2999(02)02588-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined the immunomodulatory potential of acute fenfluramine administration, by measuring production of the pro-inflammatory cytokines interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha in response to an in vivo challenge with bacterial lipopolysaccharide in rats. Fenfluramine (2.5-10 mg/kg) suppressed tumor necrosis factor-alphaproduction, but only fenfluramine (5 and 10 mg/kg) suppressed interleukin-1 p production. Fenfluramine (10 mg/kg)-induced suppression of interleukin- I and tumor necrosis factor-a production persisted for 6 and 24 h, respectively. Using in vitro analyses, we demonstrated that the immunosuppressive effect of fenfluramine was not due to a direct effect on immune cells. As fenfluramine activates the hypothalamic pituitary adrenal axis, we examined the ability of the glucocorticoid receptor antagonist mifepristone to block fenfluramine-induced immunosuppression. However, mifepristone (10 mg/kg) failed to attenuate the suppressive effect of fenfluramine on interleukin-1beta and tumor necrosis factor-alpha production, indicating that glucocorticoids do not mediate fenfluramine-induced immunosuppression. We also assessed the effect of fenfluramine on production of the anti-inflammatory cytokine interieukin-10, as interleukin-10 can suppresses pro-inflammatory cytokine production. Fenfluramine (10 mg/kg) increased interleukin-10 production following an in vivo lipopolysaccharide challenge. However, the ability of fenfluramine to suppress tumor necrosis factor-alphaproduction cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine. Taken together, these data demonstrate that fenfluramine promotes an immunosuppressive cytokine phenotype in vivo. The suppression of proinflammatory cytokines is not due to a direct effect the drug on immune cells, and also occurs independently of glucocorticoid receptor activation. In addition, whilst fenfluramine increases production of the anti-inflammatory cytokine interleukin-10, this cannot account for the suppression of the pro-inflammatory cytokine tumor necrosis factor-a induced by fenfluramine. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:175 / 185
页数:11
相关论文
共 50 条
  • [1] The antiglucocorticoid action of mifepristone
    Agarwal, MK
    [J]. PHARMACOLOGY & THERAPEUTICS, 1996, 70 (03) : 183 - 213
  • [2] BEUTLER B, 1995, J INVEST MED, V43, P227
  • [3] BOGDAN C, 1992, J BIOL CHEM, V267, P23301
  • [4] CHAOULOFF F, 1992, J PHARMACOL EXP THER, V260, P1008
  • [5] Clausing P, 1998, J PHARMACOL EXP THER, V284, P618
  • [6] An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats
    Connor, TJ
    Kelly, JP
    Leonard, BE
    [J]. IMMUNOPHARMACOLOGY, 2000, 46 (03): : 223 - 235
  • [7] Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1β and TNF-α secretion following an in vivo lipopolysaccharide challenge
    Connor, TJ
    Kelly, JP
    McGee, M
    Leonard, BE
    [J]. LIFE SCIENCES, 2000, 67 (13) : 1601 - 1612
  • [8] Acute 3,4-methylenedioxymethamphetamine (MDMA) administration produces a rapid and sustained suppression of immune function in the rat
    Connor, TJ
    McNamara, MG
    Finn, D
    Currid, A
    O'Malley, M
    Redmond, AM
    Kelly, JP
    Leonard, BE
    [J]. IMMUNOPHARMACOLOGY, 1998, 38 (03): : 253 - 260
  • [9] Methylenedioxymethamphetamine (MDMA; 'Ecstasy') suppresses antigen specific IgG2a and IFN-γ production
    Connor, TJ
    Connelly, DB
    Kelly, JP
    [J]. IMMUNOLOGY LETTERS, 2001, 78 (02) : 67 - 73
  • [10] CONNOR TJ, 2002, BRAIN BEHAV IMMUN, V16, P177